Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Sells $2,227,692.35 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 6,799 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the completion of the transaction, the chief executive officer directly owned 98,628 shares in the company, valued at $32,315,464.20. This trade represents a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Yvonne Greenstreet also recently made the following trade(s):

• On Friday, February 13th, Yvonne Greenstreet sold 6,958 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $310.08, for a total value of $2,157,536.64.
• On Monday, January 12th, Yvonne Greenstreet sold 9,577 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $362.86, for a total value of $3,475,110.22.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $320.66 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The stock has a market cap of $42.53 billion, a PE ratio of 187.52 and a beta of 0.36. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The stock has a 50 day moving average price of $352.25 and a 200 day moving average price of $414.80.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period last year, the firm posted ($0.65) EPS. The business’s quarterly revenue was up 84.9% on a year-over-year basis. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam signed a research collaboration with Tenaya Therapeutics to discover and validate genetic targets for cardiovascular disease — deal includes about $10M upfront plus up to $1.13B in milestones, expanding Alnylam’s RNAi opportunity set beyond liver/rare diseases. Tenaya deal
• Positive Sentiment: Alnylam struck a multi‑year precision‑medicine agreement with Helix to accelerate target discovery and patient stratification — a collaboration that could improve R&D efficiency and help de‑risk development programs. Helix agreement
• Positive Sentiment: Coverage notes a Canada reimbursement decision for AMVUTTRA and ongoing trial progress for pipeline assets — these commercial developments improve near‑term revenue visibility for marketed RNAi drugs. AMVUTTRA reimbursement
• Neutral Sentiment: The market reaction to Tenaya’s stock after the deal (TNYA pulled back after a strong rally) shows partner‑stock volatility but does not directly change Alnylam’s deal economics. TNYA market reaction
• Neutral Sentiment: Short‑interest reports showing “0 shares” / 0.0 days to cover are likely a reporting glitch and are not a real driver of positioning today.
• Negative Sentiment: Multiple insiders, including CEO Yvonne Greenstreet and several EVPs, disclosed share sales (early March filings). Clustered insider selling can create near‑term negative sentiment and add selling pressure despite insiders still holding large stakes. CEO SEC filing InsiderTrades summary
• Negative Sentiment: Recent quarterly results (reported Feb. 12) missed EPS and revenue estimates, which keeps valuation under scrutiny and may limit upside until clearer revenue traction is sustained.

Analyst Ratings Changes

Several equities analysts have recently commented on ALNY shares. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Stifel Nicolaus increased their price target on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Oppenheimer began coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective on the stock. Finally, Morgan Stanley decreased their price objective on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Hsbc Holdings PLC lifted its position in Alnylam Pharmaceuticals by 22.6% in the fourth quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock valued at $35,675,000 after purchasing an additional 16,503 shares during the period. SHP Wealth Management acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $43,000. Reflection Asset Management acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $63,000. Wick Capital Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $306,000. Finally, Alpine Global Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $820,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.